UTHR Share Price

Open 115.50 Change Price %
High 115.64 1 Day -0.85 -0.74
Low 114.54 1 Week -5.20 -4.34
Close 114.60 1 Month -13.85 -10.78
Volume 372309 1 Year -12.61 -9.91
52 Week High 169.89
52 Week Low 110.90
UTHR Important Levels
Resistance 2 115.62
Resistance 1 115.20
Pivot 114.93
Support 1 114.00
Support 2 113.58
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

United Therapeutics Corporation (NASDAQ: UTHR)

UTHR Technical Analysis 5
As on 22nd Sep 2017 UTHR Share Price closed @ 114.60 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 133.89 & Strong Sell for SHORT-TERM with Stoploss of 128.27 we also expect STOCK to react on Following IMPORTANT LEVELS.
UTHR Target for September
1st Target up-side 138.34
2nd Target up-side 143.62
3rd Target up-side 148.9
1st Target down-side 123.26
2nd Target down-side 117.98
3rd Target down-side 112.7
UTHR Other Details
Segment EQ
Market Capital 2447069440.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.unither.com
UTHR Address
UTHR
1040 Spring Street
Silver Spring, MD 20910
United States
Phone: 301-608-9292
Fax: 301-608-9291
UTHR Latest News
Interactive Technical Analysis Chart United Therapeutics Corporation ( UTHR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on United Therapeutics Corporation
UTHR Business Profile
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents, Cell-Based Therapy, and Engineered Lungs and Lung Tissue for Transplantation. Prostacyclin analogues are stable synthetic forms of prostacyclin. Its product is Remodulin (treprostinil) Injection (Remodulin). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of pulmonary arterial hypertension (PAH). MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells.